You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

Next-Generation BTK Inhibitors for B-cell Malignancies: Improving on the Past

  • Authors: Shirley D'Sa, MD, FRCP, FRCPath; Wojciech Jurczak, MD, PhD​; Emma Rowles, RN
  • CPD Released: 1/5/2022
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 1/5/2023
Start Activity


Target Audience and Goal Statement

This educational activity is intended for a global audience of healthcare professionals, specifically hematology/oncology specialists and pathologists, and any other healthcare specialists involved in the care of patients with B-cell malignancies.

The goal of this activity is to improve physician knowledge and competence regarding effective management strategies for treatment-related side effects associated with first- and next-generation Bruton tyrosine kinase (BTK) inhibitors for B-cell malignancies.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Different side effect profiles with BTK inhibitors for B-cell malignancies
    • Effective management strategies for treatment-related side effects associated with BTK inhibitors
  • Have greater competence related to
    • Managing treatment-related side effects associated with BTK inhibitors


Disclosures

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.


Faculty

  • Shirley D'Sa, MD, FRCP, FRCPath

    Clinical Lead
    UCLH Centre for Waldenström’s Macroglobulinemia
    Consultant Hematologist and Associate Professor
    Department of Hematology at UCL NHS Foundation Trust
    London, United Kingdom

    Disclosures

    Disclosure: Shirley D’Sa, MD, FRCP, FRCPath, has the following relevant financial relationships: 
    Advisor or consultant for: BeiGene; Janssen; Sanofi
    Speaker or a member of a speakers bureau for: BeiGene; Janssen
    Grants for clinical research from: BeiGene; Janssen

  • Wojciech Jurczak, MD, PhD

    Professor of Hematology
    Department of Clinical Oncology 
    Maria Skłodowska-Curie National Research Institute of Oncology
    Krakow, Poland

    Disclosures

    Disclosure: Wojciech Jurczak, MD, PhD, has the following relevant financial relationships: 
    Advisor or consultant for: AstraZeneca; BeiGene; Janssen; Loxo; Roche; Sandoz
    Grants for clinical research from: AbbVie; AstraZeneca; Bayer; BeiGene; Celtrion; Celgene; Debbiopharm; Epizyme; Incyte; Janssen; Loxo; Merck; Mei; Morphosys; Novo Nordisk; Roche; Sandoz; Takeda; TG Therapeutics

  • Emma Rowles, RN

    Clinical Nurse Specialist
    Myeloma and Plasma Cell Disorders
    UCLH
    London, United Kingdom

    Disclosures

    Disclosure: Emma Rowles, RN, has no relevant financial relationships.

Editors

  • Keisha Peters, MSc

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Disclosure: Keisha Peters, MSc, has disclosed no relevant financial relationships.

  • Chii Shyang Fong, PhD

    Scientific Content Manager, WebMD Global, LLC

    Disclosures

    Disclosure: Chii Shyang Fong, PhD, has disclosed no relevant financial relationships.

Content Reviewer

  • Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP

    Associate Director, Accreditation and Compliance

    Disclosures

    Disclosure: Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.5 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

Next-Generation BTK Inhibitors for B-cell Malignancies: Improving on the Past

Authors: Shirley D'Sa, MD, FRCP, FRCPath; Wojciech Jurczak, MD, PhD​; Emma Rowles, RNFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CPD Released: 1/5/2022

Valid for credit through: 1/5/2023

processing....

Educational Impact Challenge

The goal of this activity is to improve physician knowledge and competence regarding effective management strategies for treatment-related side effects associated with first- and next-generation Bruton tyrosine kinase (BTK) inhibitors for B-cell malignancies.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print